SCHEMBL3379776

SCHEMBL3379776

COc1ccc(C(CCO)NC(=O)C2SCCN2S(=O)(=O)c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 1/20 0.64
LMNA P02545 3/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
RECQL P46063 1/20 0.48
MMP9 P14780 10/20 0.48
MMP1 P03956 10/20 0.48
MMP13 P45452 10/20 0.48
MMP3 P08254 8/20 0.48
MMP7 P09237 7/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
MAPT P10636 2/20 0.46
HSD11B1 P28845 1/20 0.46
MMP2 P08253 3/20 0.46
GPR88 Q9GZN0 1/20 0.44
ADAM17 P78536 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384974 0.92 PTGFR (0.58) PTGFRLMNAKDM4EALDH1A1TSHR
SCHEMBL3383620 0.91 PTGFR (0.64) PTGFRALDH1A1MMP9MMP1MMP3
SCHEMBL3382557 0.91 PTGFR (0.64) PTGFRALDH1A1MMP9MMP1MMP3
SCHEMBL3382653 0.91 PTGFR (0.64) PTGFRALDH1A1MMP9MMP1MMP3
SCHEMBL3386103 0.91 PTGFR (0.64) PTGFRALDH1A1MMP9MMP1MMP3
SCHEMBL3382579 0.91 PTGFR (0.64) PTGFRALDH1A1MMP9MMP1MMP3
SCHEMBL3384077 0.91 PTGFR (0.64) PTGFRLMNAALDH1A1TSHRMMP9
SCHEMBL3381107 0.89 PTGFR (0.73) PTGFRMMP9MMP1MMP3HSD11B1
SCHEMBL3382048 0.89 PTGFR (0.73) PTGFRMMP9MMP1MMP3HSD11B1
SCHEMBL3383804 0.89 PTGFR (0.62) PTGFRLMNAALDH1A1TSHRMMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP claimed
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor MERCK SERONO SA (CH) 2005-09-29 US claimed
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor MERCK SERONO SA (CH) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885LMNA 2782/4885KDM4E 2809/4885
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885LMNA 2782/4885KDM4E 2809/4885
US-20050215605-A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor TBXA2R, CNR2, PTGDR PTGFR 16/4885LMNA 1563/4885KDM4E 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.